With a range of treatments available for presbyopia, the challenge for clinicians is to guide patients toward the most ...

Tenpoint Therapeutics submitted a new drug application to the FDA for Brimochol PF, an eye drop for presbyopia treatment, ...

Feature Details Company Milestones and 2025 Catalysts Across Gene Therapy and Ophthalmic ProgramsNEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Dr.

Brimochol PF, a combination of brimonidine and carbachol, was found to enhance depth of focus and visual acuity in clinical ...

BRIMOCHOL PF’s combination of brimonidine and carbachol produces a “pinhole effect,” which is intended to improve depth of ...

Christina Olner, head of professional affairs UK and Ireland at CooperVision, discussed the manufacturer’s focus at 100% Optical ...

LENZ Therapeutics is progressing rapidly with its LNZ100 for presbyopia, aiming for a 2025 U.S. launch in a market valued at ...

Ace Vision Group, Inc. (“AVG” or “the Company”), an emerging medical device company on the forefront of pioneering a laser microporation therapy for the aging eye, today announced that it will host an ...

Phakic IOL technologies have undergone substantial improvements in recent years, with progressive upgrades in design and ...

LENZ Therapeutics, Inc.'s LNZ100 eye drops show strong phase 3 results for presbyopia, outperforming competitors. Click here to find out why LENZ is a Buy.

Piper Sandler analyst Biren Amin assumed coverage of Lenz Therapeutics (LENZ) with an Overweight rating with a price target of $51, up from ...

The north america vision care market is poised for steady expansion, projected to grow from USD 70,760.8 million in 2025 to a staggering USD 91,509.4 million by 2035, registering a compound annual ...